Vera Therapeutics (VERA) Liabilities and Shareholders Equity (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $621.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 1.9% year-over-year to $621.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 20.71% YoY) and the FY2025 annual result came in at $734.7 million, up 12.06% from the prior year.
• Liabilities and Shareholders Equity eased to $621.7 million in Q1 2026, from $734.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $734.7 million in Q4 2025 to a low of $131.4 million in Q3 2022.
• A 5-year average of $366.8 million and a median of $368.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 273.51% — and 2026, when it grew 1.9%.
• Tracing VERA's Liabilities and Shareholders Equity over 5 years: stood at $131.4 million in 2022, then surged by 33.56% to $175.5 million in 2023, then surged by 273.51% to $655.7 million in 2024, then rose by 12.06% to $734.7 million in 2025, then dropped by 15.38% to $621.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $621.7 million (Q1 2026), $734.7 million (Q4 2025), and $517.5 million (Q3 2025), per Business Quant data.